Lipella Pharmaceuticals Inc. 8-K Report: Key Updates and Insights

Based on the provided section of the financial report, here are the key insights extracted:

1. Entity Information:

• Company Name: Lipella Pharmaceuticals Inc.
• CIK (Central Index Key): 0001347242
• SEC File Number: 005-93847
• EIN (Employer Identification Number): 20-2388040
• Address: 7800 Susquehanna St. Suite 505, Pittsburgh, PA 15208
• Contact Number: (412) 894-1853

2. Filing Type:

• Filing Form: 8-K
• Filing Date: February 24, 2025

3. Stock Information:

• Common Stock: Par value of $0.0001 per share
• Ticker Symbol: LIPO
• Exchange: NASDAQ

4. Context Information:

• Reporting Date: As of February 24, 2025
• Measurement Units:
• • Currency: USD
  • Shares: Measured in shares
  • Per Share Value: USD per share

Summary Insights:

• The report pertains to Lipella Pharmaceuticals Inc., which is publicly traded on NASDAQ under the ticker LIPO.
• The filing is an 8-K, typically used to report unscheduled material events or corporate changes.
• The report provides essential company identification details and indicates a common stock structure with a very low par value, which may suggest a strategy to maintain flexibility in equity financing or stock options.

This information would be relevant for investors, analysts, and stakeholders interested in the company's current status and reporting activities.